- Home
- BAND vs ATXS Comparison
BAND vs ATXS Comparison
Compare BAND & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAND
- ATXS
- Stock Information
- Founded
- BAND 2000
- ATXS 2008
- Country
- BAND United States
- ATXS United States
- Employees
- BAND N/A
- ATXS N/A
- Industry
- BAND Computer Software: Prepackaged Software
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- BAND Technology
- ATXS Health Care
- Exchange
- BAND Nasdaq
- ATXS Nasdaq
- Market Cap
- BAND 358.3M
- ATXS 401.2M
- IPO Year
- BAND 2017
- ATXS 2015
- Fundamental
- Price
- BAND $13.55
- ATXS $6.89
- Analyst Decision
- BAND Buy
- ATXS Buy
- Analyst Count
- BAND 6
- ATXS 6
- Target Price
- BAND $20.80
- ATXS $32.00
- AVG Volume (30 Days)
- BAND 345.4K
- ATXS 228.1K
- Earning Date
- BAND 07-29-2025
- ATXS 08-15-2025
- Dividend Yield
- BAND N/A
- ATXS N/A
- EPS Growth
- BAND N/A
- ATXS N/A
- EPS
- BAND N/A
- ATXS N/A
- Revenue
- BAND $758,106,000.00
- ATXS N/A
- Revenue This Year
- BAND $2.36
- ATXS N/A
- Revenue Next Year
- BAND $13.56
- ATXS N/A
- P/E Ratio
- BAND N/A
- ATXS N/A
- Revenue Growth
- BAND 14.51
- ATXS N/A
- 52 Week Low
- BAND $11.33
- ATXS $3.56
- 52 Week High
- BAND $23.00
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- BAND 38.62
- ATXS 61.34
- Support Level
- BAND $12.92
- ATXS $6.31
- Resistance Level
- BAND $16.45
- ATXS $7.34
- Average True Range (ATR)
- BAND 0.76
- ATXS 0.36
- MACD
- BAND -0.30
- ATXS -0.00
- Stochastic Oscillator
- BAND 15.04
- ATXS 67.86
About BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of our revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.